Free tool
FAERS Monitor: Kevzara
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761037 or its brand name (Kevzara, Sarilumab). Reports on generic versions are filed under their own applications.
Reports
27,761
Serious
11,334
41% of reports
Hospitalization
4,564
Death reported
2,628
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain6,401
- drug ineffective6,342
- arthralgia5,500
- joint swelling4,778
- rheumatoid arthritis4,773
- condition aggravated3,892
- fatigue3,672
- rash3,411
- alopecia3,134
- abdominal discomfort3,072
- hepatic enzyme increased2,991
- systemic lupus erythematosus2,917
- pemphigus2,855
- hand deformity2,791
- swelling2,768
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 10 |
| 2016 | 15 |
| 2017 | 138 |
| 2018 | 1,262 |
| 2019 | 1,948 |
| 2020 | 1,975 |
| 2021 | 2,986 |
| 2022 | 3,195 |
| 2023 | 2,947 |
| 2024 | 4,413 |
| 2025 | 4,892 |
| 2026 | 3,980 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,026,398 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 2,855 | 223.9 | 215.1 | 489,060 |
| hand deformitySignal | 2,791 | 204.5 | 196.4 | 445,082 |
| systemic lupus erythematosusSignal | 2,917 | 67.7 | 65.4 | 176,313 |
| hepatic enzyme increasedSignal | 2,991 | 34.7 | 33.5 | 93,923 |
| rheumatoid arthritisSignal | 4,773 | 33.2 | 32.3 | 143,568 |
| joint swellingSignal | 4,778 | 31.2 | 30.4 | 134,814 |
| swellingSignal | 2,768 | 23.1 | 22.2 | 56,920 |
| abdominal discomfortSignal | 3,072 | 14.1 | 13.6 | 37,031 |
| alopeciaSignal | 3,134 | 12.3 | 11.9 | 32,216 |
| arthralgiaSignal | 5,500 | 10.1 | 9.9 | 45,622 |
| condition aggravatedSignal | 3,892 | 9.8 | 9.5 | 30,842 |
| painSignal | 6,401 | 8.0 | 7.8 | 39,749 |
| rashSignal | 3,411 | 6.0 | 5.8 | 14,286 |
| drug ineffectiveSignal | 6,342 | 3.7 | 3.6 | 13,006 |
| fatigueSignal | 3,672 | 3.6 | 3.5 | 7,073 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.